


IBD Characterization

Chen Yanover KI Research Institute, Israel

OHDSI Community Call May 24, 2022

Background

- Inflammatory bowel diseases (IBD)
 - Crohn's disease, ulcerative colitis, indeterminate colitis
- Consistently increasing incidence rates
- Significant impact on patient's and family quality of life



Kuenzig+ (2022). *Gastroenterology*



Goal, Study Design

- Goal: unified, global characterization of IBD patient cohorts
 - risk factors, symptoms, comorbidities, treatment pathways, outcomes

• Design: characterization study (à la CHARYBDIS), extracting multiple attributes in various time windows



Extracted Attributes (1)

- Demographics, condition groups, drug era groups
- 100+ IBD-specific (binary) attributes, examples
 - Risk factors: Family history of IBD, smoking
 - Related comorbidities: autoimmune diseases, malignancies
 - Symptoms: Diarrhea, abdominal pain, rectal bleeding
 - Lab tests: anemia, high CRP, high calprotectin
 - Complications: Death, hospitalization, extra-intestinal manifestations
 - Medications: immunomodulators, steroids, biologics; antibiotics, NSAIDs
 - Procedures: partial/total colectomy, colostomy, drainage of abscess
 - Vaccines: Pneumococcal, influenza, HPV, MMR
 - •



Extracted Attributes (2)

- Time windows: entire history, 1y and 30d to index date; index date to 30d, 1y, 3y, 5y, and 10y, and entire follow-up
- Strata: follow-up time (1, 3, 5, and 10 years), sex, specific age groups, race, index date year (in 5-year windows), body mass index (BMI) categories, pregnancy
- Protocol, cohort defs, analysis code available at https://github.com/ohdsi-studies/IbdCharacterization





Preliminary results

- The Ajou University School of Medicine (AUSOM) data
- IQVIA Medical Research Data - UK

	IBD		Crohn's disease		Ulcerative colitis	
	AUSOM	IMRDUK	AUSOM	IMRDUK	AUSOM	IMRDUK
Demographics						
N	1067	23852	402	6936	635	13924
Sex = Female	36.36%	51.07%	36.57%	54.44%	36.22%	49.12%
Very early onset (2-6y)	_	0.21%	_	0.25%	_	0.16%
Early onset (6-10y)	1.12%	0.70%	2.49%	1.27%	_	0.46%
Pediatrics	9.28%	6.05%	16.67%	10.90%	4.57%	3.74%
Age 18 - 65	81.26%	73.06%	73.63%	73.70%	86.46%	72.77%
Age >= 65	8.06%	19.97%	6.47%	13.88%	8.66%	22.86%
Medications (index date – 1y)						
5-ASA exposure	81.70%	81.10%	72.90%	64.50%	88.30%	88.70%
IBD antibiotics exposure	21.60%	3.80%	31.60%	4.90%	14.60%	3.10%
Topical IBD steroid exposure		3.90%		1.40%		5.30%
IBD biologics exposure	5.70%	0.10%	9.70%	0.30%	3.50%	0.00%
Immunomodulator exposure	22.30%	19.40%	35.80%	35.00%	13.90%	11.90%
Procedures (index date – 3y)						
total colectomy procedure		1.60%		0.60%		2.00%
partial colectomy procedure		4.50%		9.30%		2.50%
ileostomy procedure	_	1.20%	_	1.60%	_	1.10%









Summary

- Detailed description of disease trajectory in IBD patients
- Characteristics of Korean and British IBD cohorts; 3 Israeli hospitals (awaiting IRB approval) join us!
- Setting the stage for related prediction and estimation research projects



Collaborators

Rambam Medical Center

- Ramit Magen-Rimon
- Yehuda Chowers
- Roni Weisshof

KI Research Institute

- Tal El-Hay
- Maytal Bivas-Benita
- Pinchas Akiva

Ajou University

- Jimyung Park
- Rae Woong Park
- Kwang Jae Lee
- Sung Jae Shin

Ben-Gurion University

Nadav Rappoport

